Evidence map›Paper›PMID 39192378›Full record

ReviewTranslational neurodegeneration2024

Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures.

Chao Gao, Ran Xiong, Zhi-Yu Zhang, Hua Peng, Yuan-Kai Gu, Wei Xu, Wei-Ting Yang, Yan Liu, Jie Gao, You Yin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chao Gao *Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China.
Ran Xiong *Department of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Zhi-Yu Zhang *Department of Health Management, Second Affliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China.
Hua Peng *Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China.
Yuan-Kai GuDepartment of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China.
Wei XuDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Wei-Ting YangDepartment of Neurology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China.
Yan LiuDepartment of Clinical Pharmacy, Xinhua Hospital, Clinical Pharmacy Innovation Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, 200000, China. liuyan@shsmu.edu.cn.
Jie GaoChanghai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. gaojiehighclea@smmu.edu.cn.
You YinDepartment of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China. yinyou179@163.com.ORCID 0000-0001-9657-9720

Funding

Innovative Research Team of High-level Local University in Shanghai 2020YLCYJ-Y02；2020CZWJFW12Innovative Research Team of High-level Local University in Shanghai 2023YJBF-PY13Natural Science Foundation of Xiaogan Municipality 22ZR147750Science and Technology Innovation Action Plan of Shanghai Science and Technology Commission 23Y11906600Shanghai Aerospace Science and Technology Innovation Foundation BSCX2023-19；BSCX2022-34
6 · The paper itself

Abstract

The diagnosis of neurodegenerative diseases (NDDs) remains challenging, and existing therapeutic approaches demonstrate little efficacy. NDD drug delivery can be achieved through the utilization of nanostructures, hence enabling multimodal NDD theranostics. Nevertheless, both biomembrane and non-biomembrane nanostructures possess intrinsic shortcomings that must be addressed by hybridization to create novel nanostructures with versatile applications in NDD theranostics. Hybrid nanostructures display improved biocompatibility, inherent targeting capabilities, intelligent responsiveness, and controlled drug release. This paper provides a concise overview of the latest developments in hybrid nanostructures for NDD theranostics and emphasizes various engineering methodologies for the integration of diverse nanostructures, including liposomes, exosomes, cell membranes, and non-biomembrane nanostructures such as polymers, metals, and hydrogels. The use of a combination technique can significantly augment the precision, intelligence, and efficacy of hybrid nanostructures, therefore functioning as a more robust theranostic approach for NDDs. This paper also addresses the issues that arise in the therapeutic translation of hybrid nanostructures and explores potential future prospects in this field.

Indexed as

NanostructuresNeurodegenerative DiseasesTheranostic NanomedicineAnimalsDrug Delivery SystemsHumansAlzheimer's diseaseBiomembraneDiagnosisHybrid nanostructureNeurodegenerative diseasesParkinson's disease

Identifiers

PMID39192378
PMCPMC11348682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.